2 Biotech Stocks to Buy Hand Over Fist in December
Portfolio Pulse from
The biotech industry has underperformed the broader market in 2024, with the SPDR S&P Biotech ETF up 9% compared to the S&P 500's 28%.
December 07, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The SPDR S&P Biotech ETF has gained 9% in 2024, underperforming the S&P 500's 28% increase.
The SPDR S&P Biotech ETF's performance is directly mentioned, highlighting its underperformance relative to the S&P 500. This suggests a neutral short-term impact as the information is already known.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80